Allogene Therapeutics (ALLO) EBT Margin (2021 - 2025)
Historic EBT Margin for Allogene Therapeutics (ALLO) over the last 4 years, with Q1 2024 value amounting to 291231.82%.
- Allogene Therapeutics' EBT Margin rose 322115200.0% to 291231.82% in Q1 2024 from the same period last year, while for Dec 2024 it was 1151031.82%, marking a year-over-year decrease of 8253160300.0%. This contributed to the annual value of 1168850.0% for FY2024, which is 8243605300.0% down from last year.
- Per Allogene Therapeutics' latest filing, its EBT Margin stood at 291231.82% for Q1 2024, which was up 322115200.0% from 375447.62% recorded in Q4 2023.
- Allogene Therapeutics' EBT Margin's 5-year high stood at 2.5% during Q4 2021, with a 5-year trough of 375447.62% in Q4 2023.
- Over the past 4 years, Allogene Therapeutics' median EBT Margin value was 258140.91% (recorded in 2023), while the average stood at 223087.67%.
- Its EBT Margin has fluctuated over the past 5 years, first tumbled by 2000000000bps in 2022, then surged by 437442800bps in 2023.
- Allogene Therapeutics' EBT Margin (Quarter) stood at 2.5% in 2021, then crashed by -14392819bps to 360146.15% in 2022, then decreased by -4bps to 375447.62% in 2023, then increased by 22bps to 291231.82% in 2024.
- Its EBT Margin was 291231.82% in Q1 2024, compared to 375447.62% in Q4 2023 and 258140.91% in Q3 2023.